Deep Brain Stimulation for Refractory PTSD

NCT ID: NCT06705296

Last Updated: 2024-11-26

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-11-01
• Study Completion Date: 2026-11-01

Brief Summary

Treatment refractory PTSD is a chronic and debilitating psychiatric disorder associated with high morbidity. Despite advances in neuroimaging, genetics, pharmacology and psychosocial interventions in the last half century, little progress has been made in altering the natural history of the condition or its outcome.

This study would be the first exploration of a surgical therapy for refractory PTSD. The subgenual cingulate plays a role in mechanisms of this disorder and has been successfully targeted with DBS for the treatment of depression

The study will proceed in three stages: pre-operative, operative and post-operative. In the pre-operative stage, consent will be obtained and patients will be scheduled for additional investigations, including neuroimaging (MRI), neuropsychological testing, psychophysiological testing, and a pre-operative assessment by the anesthesia service.

In the operative stage, patient will have a stereotactic frame attached directly to their skull. The patient will then undergo a computed tomography (CT) scan with the frame in place, followed by transport directly to the operating room. A skin incision will be made and two burr holes drilled through the skull. After target identification DBS electrodes will be inserted and fixed in place. Patients will be then immediately anesthetized (general anesthesia) for the next step of the surgery. This will involve implanting an internal pulse generator (IPG) under the collarbone and connecting it to the DBS electrodes.

During the post-operative phase, patients will return to the clinic 2 weeks after surgery.DBS programming visits will happen biweekly for three months, and monthly thereafter.

Detailed Description

Treatment refractory PTSD is a chronic and debilitating psychiatric disorder associated with high morbidity. Despite advances in neuroimaging, genetics, pharmacology and psychosocial interventions in the last half century, little progress has been made in altering the natural history of the condition or its outcome. It has further become increasingly accepted that this condition results, at least in part, from dysfunctional neuroanatomic circuits, whose activity and deviations can be detected with sophisticated neuroimaging techniques. Much progress has also been made in mapping the psychology of the illness to underlying neuroanatomic and neurophysiologic processes that drive and maintain these behaviours.

This study would be the first exploration of a surgical therapy for refractory PTSD. The subgenual cingulate plays a role in mechanisms of this disorder and has been successfully targeted with DBS for the treatment of depression (a highly incident co-morbidity in patients with treatment refractory PTSD).

There are currently no brain based, targeted therapies for treatment refractory PTSD with or without co-morbid depression (only the few patients described above). This study will be the first powered clinical trial exploring deep brain stimulation in this patient population.

This is a phase I, non-randomized, pilot trial for safety and efficacy of deep brain stimulation for PTSD. Patients who meet inclusion and exclusion criteria will be identified and recruited from the practices of Sunnybrook psychiatrists. The study will proceed in three stages: pre-operative, operative and post-operative. In the pre-operative stage, consent will be obtained and patients will be scheduled for additional investigations, including neuroimaging (MRI), neuropsychological testing, psychophysiological testing, and a pre-operative assessment by the anesthesia service. A clinical interview will be used to understand experiences of patients and a family member of each patient (i.e. parent, significant other, spouse, partner, informant, etc.). In the operative stage, patient will have a stereotactic frame attached directly to their skull. The patient will then undergo a computed tomography (CT) scan with the frame in place, followed by transport directly to the operating room. A skin incision will be made and two burr holes drilled through the skull. After target identification DBS electrodes will be inserted and fixed in place. Patients will be then immediately anesthetized (general anesthesia) for the next step of the surgery. This will involve implanting an internal pulse generator (IPG) under the collarbone and connecting it to the DBS electrodes . Once surgery is over, the patient will be woken up, extubated, and transferred to the recovery room. From there, patients will go to the to the neurosurgical ward (D5). During the post-operative phase, patients will return to the clinic 2 weeks after surgery.DBS programming visits will happen biweekly for three months, and monthly thereafter. Twenty (20) subjects will be enrolled and study duration for each patient will be of 60 weeks.

The study will consist of four (4) phases to be detailed below: 1) Open label phase (from surgery until postoperative week 24); 2) Double-blinded "on/off" phase (from postoperative week 25 to 33); 3) Prolonged exposure therapy (from postoperative week 34 to 44); 4) Closed-loop DBS (from postoperative week 45 to 60).

We believe that the scientific significance lay above all, in the development of a novel treatment alternative in the significant portion of this patient population who fail to respond to currently available treatments. The development of a therapy that targets brain structures known to play a role in this disease would be a substantial step forward in the treatment and understanding of these conditions.

Conditions

PTSD

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Open label

1\) Open label phase (from surgery until postoperative week 24)

Group Type: EXPERIMENTAL

Open Label Deep Brain Stimulation

Intervention Type: DEVICE

Patients will receive open label deep brain stimulation

Double-blinded "on/off" phase

Double-blinded "on/off" phase (from postoperative week 25 to 33)

Group Type: PLACEBO_COMPARATOR

Double blinded Deep Brain Stimulation

Intervention Type: DEVICE

Patients will receive double blinded deep brain stimulation

Prolonged exposure therapy

Prolonged exposure therapy (from postoperative week 34to 44)

Group Type: EXPERIMENTAL

Prolonged exposure therapy

Intervention Type: BEHAVIORAL

Patients will receive prolonged exposure therapy

Closed-loop DBS

Closed-loop DBS (from postoperative week 45 to 60).

Group Type: EXPERIMENTAL

Closed loop Deep brain stimulation

Intervention Type: DEVICE

Patients will receive closed loop deep brain stimulation

Interventions

Open Label Deep Brain Stimulation

Patients will receive open label deep brain stimulation

Intervention Type: DEVICE

Double blinded Deep Brain Stimulation

Patients will receive double blinded deep brain stimulation

Intervention Type: DEVICE

Prolonged exposure therapy

Patients will receive prolonged exposure therapy

Intervention Type: BEHAVIORAL

Closed loop Deep brain stimulation

Patients will receive closed loop deep brain stimulation

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Female or Male patients between age 18-70

2. Diagnosis of posttraumatic stress disorder as defined by the Diagnostic and Statistical Manual fifth edition (DSM-5).

3. Treatment Resistance as defined by the persistence of clinical symptoms despite adequate treatment with four modalities, including a) selective serotonin reuptake inhibitors, b) cognitive behavioral therapy, c) other classes of medications and/or psychotherapy.

4. Severe forms of the disease as measured by Clinician Administered PTSD scale (CAPS) scores≥ 50.

5. A pattern of chronic stable PTSD lasting at least 1 year.

6. Ability to provide informed consent and comply with all testing, follow-ups and study appointments and protocols.

Exclusion Criteria

1. Any past or current evidence of psychosis or mania (patients with co-morbid depression will not be excluded from the study)

2. Active neurologic disease, such as epilepsy

3. Alcohol or substance dependence or abuse in the last 6 months, excluding caffeine and nicotine.

4. Current suicidal ideation

5. Any contraindication to MRI or PET scanning

6. Likely to relocate or move out of the country during the study's duration.

7. Presence of clinical and/or neurological conditions that may significantly increase the risk of the surgical procedure.

8. Currently pregnant (as determined by history and serum HCG) or lactating; for females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sunnybrook Health Sciences Centre

OTHER

Sponsor Role: lead

Responsible Party

Dr. Nir Lipsman

Neurosurgeon

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Nir Lipsman, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Sunnybrook Health Sciences Centre

Locations

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

Site Status: RECRUITING

Countries

Canada

Central Contacts

Anusha Baskaran, PhD

Role: CONTACT

anusha.baskaran@sunnybrook.ca

416-480-6100 ext. 61650

Facility Contacts

Anusha Baskaran, PhD

Role: primary

anusha.baskaran@sunnybrook.ca

416-480-6100 ext. 61650

Other Identifiers

6355

Identifier Type: -

Identifier Source: org_study_id